3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Tuberous Sclerosis
1
Stomach Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Myasthenia Gravis
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Biphenotypic, Acute
1
Epilepsy
1
Diffuse Intrinsic Pontine Glioma
1
Cut-Off Value
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Endometrioid
1
Breast Neoplasms
1
Breast Cancer Lymphedema
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Interventions
Everolimus
18
Sirolimus
15
Cannabidiol
5
radiprodil
3
ganaxolone
3
Vigabatrin
3
Activator Appliances
3
Melatonin
2
exemestane
1
dactolisib
1
carbon-11 acetate
1
Surveys and Questionnaires
1
Simvastatin
1
Sertraline
1
Selective Serotonin Reuptake Inhibitors
1
Propranolol
1
Itraconazole
1
Injections
1
Fluid Therapy
1
Doxycycline
1
Curcumin
1
Carbamazepine
1
Calcitriol
1
Aspirin
1
Anticonvulsants
1
Actigraphy
1
Acceptance and Commitment Therapy
1
2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Tuberous Sclerosis
×
Fluid Therapy
×
Clear all
NCT04987463
2024-02-08
ViRap
Children's Memorial Health Institute, Poland
Phase 2/3
Unknown
60 enrolled